Market Intelligence, Clinical Progress, and High-Purity Reagents for Epilepsy and Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KCNQ2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Membrane Protein | KCNQ2 Lentivirus Premade Particles For stable cell line construction. Cell-based assays are the only way to preserve conformation. Sequence Verified. |
View KCNQ2 Products |
| Gene Delivery | KCNQ2 Promise-ORF Full-length ORF for stable cell lines. High Purity (>95%), Endotoxin Controlled. |
View KCNQ2 Products |
| Benchmark Ab | Anti-KCNQ2 Recombinant Antibody Recombinant positive control for western blot and target engagement. |
View KCNQ2 Products |
| Validator | KCNQ2 siRNA Set For knockdown verification in target specificity assays. |
View KCNQ2 Products |
| Related Target A | KCNQ3 Forms heteromeric Kv7.2/7.3 M-channels with KCNQ2; essential for physiological functional assays. |
View KCNQ3 Products |
| Related Target B | SCN1A Voltage-gated sodium channel, synergistic screening target for broad-spectrum anti-epileptic profiling. |
View SCN1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation (Ion Channel) | Lentivirus-mediated stable cell line generation ensures native multi-pass transmembrane folding. |
| Subfamily Counter Screening (Selectivity) | Homolog panel (KCNQ3, KCNQ4, KCNQ5) ORFs strictly verified by sequencing for specificity testing. |
| Lack of Controls | Clinical Benchmark Antibodies included for precise assay standardization. |
| False Positives | Validatable siRNA sets included for rigorous biological background checks. |
Key Known Mutations in KCNQ2
The following mutations are clinically documented in KCNQ2-related disorders (source: UniProt O43526):
| Mutation (dbSNP) | Associated Condition |
|---|---|
| rs1057516076 | Benign Familial Neonatal Seizures type 1 (BFNS1) |
| rs1057516078 | BFNS1 with infantile seizures |
| rs1057516081 | Benign Familial Neonatal Seizures type 1 (BFNS1) |
Live KCNQ2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNQ2 therapeutics is intensifying, with major players shifting focus from early-generation broadly acting channel openers to highly selective Small Molecules and Precision Genetic Modulators. As first-generation therapies mapped the mechanism of action, the next wave of R&D is targeting pediatric developmental and epileptic encephalopathies (KCNQ2-DEE) through subtype-selective positive allosteric modulators (PAMs) that minimize off-target adverse effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAM) | Xenon Pharmaceuticals, Biohaven | KCNQ2-DEE, Focal Epilepsy | Patch Clamp / Thallium Flux (Need robust Lentivirus for KCNQ2/3 cell lines) |
| Antisense Oligo (ASO) | Stoke Therapeutics (General Epilepsies) | Genetic Epilepsies | Expression Modulation (Need precise siRNA / Western Blot Ab controls) |
| Gene Therapy | Academic/Biotech Consortiums | Neonatal Seizures | Functional Rescue (Need Full-length ORF & Native HEK293 expression) |